FITC标记的蛋白C抑制因子抗体
产品名称： FITC标记的蛋白C抑制因子抗体
英文名称： Anti-Protein C inhibitor/FITC
产品编号： HZ-5793R-FITC
产品价格： null
产品产地： 中国/上海
品牌商标： HZbscience
更新时间： 2023-08-17T10:24:20
使用范围： IF=1:50-200
上海沪震实业有限公司
- 联系人 : 鲍丽雯
- 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
- 邮编 : 200612
- 所在区域 : 上海
- 电话 : 139****0749 点击查看
- 传真 : 点击查看
- 邮箱 : www.shzbio.net
- 二维码 : 点击查看
Rabbit Anti-Protein C inhibitor/FITC Conjugated antibody
FITC标记的蛋白C抑制因子抗体
| 英文名称 | Anti-Protein C inhibitor/FITC |
| 中文名称 | FITC标记的蛋白C抑制因子抗体 |
| 别 名 | Acrosomal serine protease inhibitor; IPSP; PAI 3; PAI3; PCI; PLANH 3; PLANH3; Plasma serine protease inhibitor; Plasminogen activator inhibitor 3; Plasminogen activator inhibitor III; PROCI; Serpin A5; Serpin peptidase inhibitor clade A (alpha 1 antiproteinase antitrypsin) member 5; Serpin peptidase inhibitor clade A member 5; SerpinA5; IPSP_HUMAN. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 肿瘤 心血管 免疫学 细胞凋亡 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Chicken, Dog, Cow, Sheep, |
| 产品应用 | IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 43kDa |
| 细胞定位 | 细胞膜 |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Protein C inhibitor |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: Protein C Inhibitor (PCI), a member of the serine protease inhibitor (serpin) superfamily, is abundant in plasma and other body fluids. Protein C Inhibitor inhibits a number of "arginine specific" serine proteases of the coagulation and fibrinolytic systems (including thrombin, trypsin, and activated Protein C), as well as plasma and tissue kallikreins and the sperm protease acrosin. This inhibition is regulated by glycosaminoglycans, such as heparin and heparan sulphate, and several polyanions. As well as its roles in the regulation of hemostasis and fertilisation, Protein C Inhibitor is involved in cell inflammation, proliferation, apoptosis, tumour cell migration, invasion, and metastasis. Recent studies have demonstrated an association between Protein C Inhibitor and multiple sclerosis lesions. Function: Heparin-dependent serine protease inhibitor acting in body fluids and secretions. Inactivates serine proteases by binding irreversibly to their serine activation site. Involved in the regulation of intravascular and extravascular proteolytic activities. Plays hemostatic roles in the blood plasma. Acts as a procoagulant and proinflammatory factor by inhibiting the anticoagulant activated protein C factor as well as the generation of activated protein C factor by the thrombin/thrombomodulin complex. Acts as an anticoagulant factor by inhibiting blood coagulation factors like prothrombin, factor XI, factor Xa, plasma kallikrein and fibrinolytic enzymes such as tissue- and urinary-type plasminogen activators. In seminal plasma, inactivates several serine proteases implicated in the reproductive system. Inhibits the serpin acrosin; indirectly protects component of the male genital tract from being degraded by excessive released acrosin. Inhibits tissue-and urinary-type plasminogen activator, prostate-specific antigen and kallikrein activities; has a control on the sperm motility and fertilization. Inhibits the activated protein C-catalyzed degradation of SEMG1 and SEMG2; regulates the degradation of semenogelin during the process of transfer of spermatozoa from the male reproductive tract into the female tract. In urine, inhibits urinary-type plasminogen activator and kallikrein activities. Inactivates membrane-anchored serine proteases activities such as MPRSS7 and TMPRSS11E. Inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis. May also play a non-inhibitory role in seminal plasma and urine as a hydrophobic hormone carrier by its binding to retinoic acid. Subunit: Forms protease inhibiting heterodimers in extracellular body fluids with serine proteases such as activated protein C/coagulation factor V/F5, acrosin/ACR, chymotrypsinogen B/CTRB1, prothrombin/F2, factor Xa/F10, factor XI/F11, kallikrein/KLKB1, tissue kallikrein, trypsin/PRSS1, prostate specific antigen/KLK3, tissue plasminogen activator/PLAT and urinary plasminogen activator/PLAU. Forms membrane-anchored serine proteases inhibiting heterodimers with TMPRSS7 and TMPRSS11E. Interacts with SEMG2. Subcellular Location: Secreted, extracellular space. Note=Localized on the plasma membrane overlying the acrosomal head of spermatozoa of ependymal spermatozoa and ejaculated sperm. Localized at the equatorial segment of acrosome-reacted spematozoa. Localized in alpha granules in resting platelets and on the external plasma membrane and within the surface-connected cannalicular system in activated platelets. Tissue Specificity: Predominantly expressed in the epithelium of seminal vesicles. Expressed in the proximal tubular epithelium of the kidney. Expressed in the superficial and more differentiated epidermal keratinocytes of the skin. Expressed in megakaryocytes and platelets. Expressed poorly in kidney tumor cells compared to non tumor kidney tissues. Expressed in spermatozoa. Present in very high concentration in seminal plasma. Present in high concentration in plasma, synovial and Graaf follicle fluids. Present in low concentration in breast milk and in amniotic fluids. Present in very low concentration in urine, cerebrospinal fluids, saliva and tears (at protein level). Strongly expressed in liver. Expressed in kidney, spleen, pancreas, skeletal muscle, heart, testes, ovary, interstitial Leydig cells, epididymal glands, seminal vesicles and prostate. Post-translational modifications: N- and O-glycosylated. N-glycosylation consists of a mixture of sialylated bi- (including sialyl-Lewis X epitopes), tri- and tetra-antennary complex-type chains; affects the maximal heparin-and thrombomodulin-enhanced rates of thrombin inhibition. O-glycosylated with core 1 or possibly core 8 glycans. Further modified with 2 sialic acid residues. Proteolytically cleaved. Inhibition of proteases is accompanied by formation of a stable enzyme-inhibitor complex and by degradation of the serpin to lower molecular weight derivatives. Proteolytically cleaved at the N-terminus; inhibits slightly the heparin- and thrombomodulin-enhanced rates of thrombin inhibition. Similarity: Belongs to the serpin family. Database links: Entrez Gene: 5104 Human Omim: 601841 Human SwissProt: P05154 Human Unigene: 159628 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications |
蛋白C抑制剂（PCI）是丝氨酸蛋白酶抑制剂（Serpin）超家族成员，在血浆和其他体液中含量丰富。蛋白C抑制剂抑制凝血和纤溶系统（包括凝血酶、胰蛋白酶和活化蛋白C）以及血浆和组织激肽释放酶和精子蛋白酶顶体酶的“精氨酸特异性”丝氨酸蛋白酶的数量。这种抑制是由糖胺聚糖调节的，如肝素和硫酸乙酰肝素，以及一些聚阴离子。蛋白C抑制剂及其在调节止血和受精中的作用涉及细胞炎症、增殖、凋亡、肿瘤细胞迁移、侵袭和转移。最近的研究表明，蛋白C抑制剂和多发性硬化病变之间的关联。